Uses of cerberus, coco and derivatives thereof

Details Uses of cerberus, coco and derivatives thereof Uses of cerberus, coco and derivatives thereof

2007-12-10

2010-11-16

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07833971

ABSTRACT:
The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.

REFERENCES:
patent: 5935852 (1999-08-01), Follettie et al.
patent: 6133232 (2000-10-01), De Robertis et al.
patent: 6610510 (2003-08-01), Valenzuela et al.
patent: 7316998 (2008-01-01), Knopf et al.
patent: 2002/0164682 (2002-11-01), Follettie et al.
patent: 2003/0134790 (2003-07-01), Langenfeld
patent: 2003/0194704 (2003-10-01), Penn et al.
patent: 2003/0199042 (2003-10-01), Valenzuela et al.
patent: 2004/0005560 (2004-01-01), Isogai et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2005/0186663 (2005-08-01), Davies et al.
patent: 2006/0105376 (2006-05-01), Isogai et al.
patent: 2008/0032304 (2008-02-01), Isogai et al.
patent: 1347046 (2003-09-01), None
patent: WO-97/48275 (1997-12-01), None
patent: WO-98/34951 (1998-08-01), None
patent: WO-98/49296 (1998-11-01), None
patent: WO-99/01553 (1999-01-01), None
patent: WO-99/40181 (1999-08-01), None
patent: WO-00/55193 (2000-09-01), None
patent: WO-02/10214 (2002-02-01), None
patent: WO-02/32929 (2002-04-01), None
patent: WO-02/054940 (2002-07-01), None
patent: WO-02/077204 (2002-10-01), None
patent: WO-02/078516 (2002-10-01), None
patent: WO-02/090992 (2002-11-01), None
patent: WO-03/055443 (2003-01-01), None
patent: WO-03/012082 (2003-02-01), None
patent: WO-03/055911 (2003-07-01), None
patent: WO-03/072714 (2003-09-01), None
patent: WO-03/106657 (2003-12-01), None
patent: WO-2004/074460 (2004-09-01), None
patent: WO-2005/003158 (2005-01-01), None
patent: WO-2005/115439 (2005-12-01), None
Avsian-Kretchmer et al., “Comparative geneomic analysisof the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists,” Molecular Endocrinology 18(1):1-12 (2004).
Belo et al., “Cerberus-likeis a secreted factor with nerualizing activity expressed in the anterior primitive endoderm of the mouse gastrula,” Mechanisims of Development 68:45-57 (1997).
Biben et al., “Murine Cerberus Homologue mCer-1: A canadidate anterior patterning molecule,” Developmental Biology 194:135-151 (1998).
Bouwmeester et al., “Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer,” Nature 382:595-601 (1996).
Esteban et al., “The novel Cer-like protein Caronte mediates the extablishment of embryonic left-right asymmetry,” Nature 401:243-251 (1999).
Katoh et al., “Identification and characterization of humanCKTSF1B2andCKTSF1B3genes in silico,” Oncology Reports 12:423-427 (2004).
Kuroda et al., “Neural Induction inXenopus:requirement for extodermal and endomesodermal signals via chordin, noggin, β-catenin and cerberus,” PLoS Biology 2(5):0623-0634 (2004).
Lah et al., “Humancerberusrelated geneCER1maps to chromosome 9,” Genomics 55:364-366 (1999).
Marques et al., “The activity of the nodal antagonistCerl-2in the mouse node is required for correct L/R body axis,” Genes & Development 18:2342-2347 (2004).
Pearce et al., “A mouse cerberus/dan-related gene family,” Developmental Biology 209:98-110 (1999).
Piccolo et al., “The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals,” Nature 397:707-710 (1999).
Silva et al., “Endogenous Cerberus activity is required for anterior head specification inXenopus,” Development 130(20):4943-4953 (2003).
Stanley et al., “MurinecerberushomologueCer1maps to chromosome 4,” Genomics 49:337-338 (1998).
Motoko Yanagita. BMP antagonists: Their roles in development and involvement in pathophysiology. Cytokine and Growth Factor Reviews. vol. 16, No. 3, pp. 309-319. 2005.
Brecher, A.S., et al., “Acetaldehyde Inhibits Chymotrypsin and Serum Anti-Chymotrypsin Activity,” J. Investig Med., 46(4):146-152 (1998). Abstract only.
Livingston, S.F., et al., “The Significance of Chymotrypsin-Inhibitor Levels in the Serum of Patients with Carcinoma of the Breast,” Cancer Research, 17(9):857-861 (1957).

Affiliated with

Also associated with

Rating

Uses of cerberus, coco and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of cerberus, coco and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of cerberus, coco and derivatives thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171633